Elite Express Holding Inc. Announces Pricing of $15.2 Million Initial Public Offering
The shares of Class A common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol 'ETS' on August 21, 2025. The offering is expected to close on August 22, 2025, subject to the satisfaction of customary closing conditions.
Dominari Securities LLC is acting as the representative of the underwriters for the offering, with Revere Securities acting as co-underwriter for the offering. Pacific Century Securities, LLC is acting as the advisor to ETS.
A registration statement on Form S-1 (File No. 333-286965), as amended, was filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective on August 20, 2025. The offering is being made only by means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus may be obtained from the underwriter by contacting Dominari Securities LLC at 725 Fifth Avenue, 23rd Floor, New York, NY 10022, by calling (212) 393-4500 or (800) 299-7618, or by emailing info@dominarisecurities.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Elite Express Holding Inc.
ETS is a Delaware holding company that conducts its operations through its wholly owned subsidiary, JAR Transportation Inc., based in California. ETS provides last-mile delivery services, primarily focused on transporting packages from distribution centers to end customers within defined service areas. Leveraging logistics software to support route planning, driver oversight, and regulatory compliance, ETS is committed to enhancing operational efficiency and service reliability through the use of technology-driven solutions.
Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements about the anticipated timing of the offering. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'anticipate,' 'believe,' 'continue,' 'estimate,' 'expect,' 'future,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would,' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. These statements relate to future events, including, but not limited to, statements relating to the expected closing date of the offering and expected gross proceeds from the offering. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ include risks related to our ability to satisfy the closing conditions related to the offering, general market and economic conditions, and those other risks as are detailed in ETS' filings with the SEC, including the registration statement on Form S-1 under the section 'Risk Factors.' ETS undertakes no obligation to update forward-looking statements except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
6 minutes ago
- CTV News
Tiger Woods to lead group that could reshape the PGA Tour's competitive model
Tiger Woods waves after his final round at the Masters golf tournament at Augusta National Golf Club Sunday, April 14, 2024, in Augusta, Ga. (AP Photo/David J. Phillip) ATLANTA — Tiger Woods is a major player in golf again, this time without clubs. He was appointed Wednesday to chair a new committee charged with taking a fresh look at the competitive model for how the PGA Tour runs its tournaments. Brian Rolapp, three weeks into his role as the tour's first CEO, announced the nine-member 'Future Competition Committee' and said it would have a clean sheet to consider changes that uphold traditions without being tied to them. 'This is about shaping the next era of the PGA Tour,' Woods said in a social media post. Rolapp didn't have details on several issues he faces as he takes over for Commissioner Jay Monahan, including the future of a sport that has been splintered by Saudi money that created the rival LIV Golf League and lured away a number of top players. The PGA Tour's negotiations with the Public Investment Fund have stalled, and Rolapp did not make that sound as if it were a top priority when asked about the fans' desire to see all the best players together more often. 'I'm going to focus on what I can control,' Rolapp said. 'I would offer to you that the best collection of golfers in the world are on the PGA Tour. I think there's a bunch of metrics that demonstrate that, from rankings to viewership to whatever you want to pick. I'm going to lean into that and strengthen that. 'I will also say that to the extent we can do anything that's going to further strengthen the PGA Tour, we'll do that,' he said. 'And I'm interested in exploring whatever strengthens the PGA Tour.' Woods, who has played only 10 times on the PGA Tour since his February 2021 car crash and has been out all of this year with a ruptured Achilles tendon, already serves on the PGA Tour board without a term limit. Now he will lead five players from the board — Patrick Cantlay, Adam Scott, Camilo Villegas, Maverick McNealy and Keith Mitchell — along with three from the business side. That includes baseball executive Theo Epstein. Rolapp is not trying to reinvent a sport that held its first championship in 1860. He said among his early observations, after two decades at the NFL, was the strength and momentum of the PGA Tour. 'My key takeaway when you boil all this down is that the strength of the PGA Tour is strong, but there's much more we need to do, much more we need to change for the benefit of fans, players and our partners,' he said. He said the committee would be guided by parity (he conceded golf already has that), scarcity and simplicity. The tour released a 2026 schedule on Tuesday that adds another US$20-million signature event, this one to Trump National Doral, as part of a 35-event schedule from January through August. Rolapp said the simplicity was mostly about connecting the regular season to the postseason. He referred to the committee's work as a 'holistic relook of how we compete on the tour' during the regular season, postseason and offseason. 'The goal is not incremental change,' he said. 'The goal is significant change.' He did not set a timetable for any of it. The Tour Championship ends this week at East Lake for the top 30 players. The tour has eliminated the built-in advantage for top seeds so that everyone starts from scratch. The committee is a smaller version of the PGA Tour Enterprises board and policy board. Joining Epstein from the business side are board chairman Joe Gorder and John Henry of Fenway Sports Group, who leads the Strategic Sports Group that invested $1.5 billion — with the potential to double that — into the tour in a minority investment announced 18 months ago. Rolapp said he had a lot of ideas how to the use the money but none he was ready to share. But he said the involvement of SSG was a big reason he took the job. 'Not only does it provide necessary capital as we work through this competitive model and improved commercial model, I also think it also brings learnings from other sports, which I think is beneficial ... to grow the PGA Tour. 'I think outside perspective is always a very good thing, as long as it's applied in the right way. I think SSG has brought that and has been helpful.' ___ Doug Ferguson, The Associated Press
Globe and Mail
6 minutes ago
- Globe and Mail
Satellos to Participate in Four September Institutional and Retail Investor Conferences
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today that members of its senior management team will participate in the following investor events in September: Wells Fargo Healthcare Conference Format: Participation in 1x1 meetings Date: Wednesday, Sept. 3 Location: Boston, MA Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat and 1x1 meetings Date: Friday, Sept. 5, 10:55 ET Location: New York, NY H.C. Wainwright Global Investment Conference Format: Participation in 1x1 meetings Date: Tuesday, Sept. 9 Location: New York, NY Morgan Stanley Global Healthcare Conference Format: Fireside Chat and 1x1 meetings Date: Wednesday, Sept. 10, 9:15 ET Location: New York, NY Should any retail or institutional investors wish to connect directly with us in person, please reach out to us at ir@ The fireside chats will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentations. ABOUT SATELLOS BIOSCIENCE INC. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit NOTICE ON FORWARD-LOOKING STATEMENTS This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective', 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise.
Globe and Mail
6 minutes ago
- Globe and Mail
BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer
POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies. Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately $100,000. The purchases were made through two separate transactions: 2,500 shares at an average price of $6.28 and 13,000 shares at an average price of $6.51. Following these transactions, Mr. Matuszewski owns 1,145,362 shares of BioStem Technologies stock. For more information about the purchases, please visit the OTCID disclosure website HERE under Officer/Director/Affiliate Stock Transactions. About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE ®, VENDAJE AC ®, and VENDAJE OPTIC ®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. Investor Relations: Adam Holdsworth, BioStem Director of Investor Relations E-Mail: adam@ Phone: 917-497-9287 Or Gilmartin Group Philip Trip Taylor, Principal E-Mail: philip@ Phone: 415-937-5406
